Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Harrow Health Inc.

    NASDAQ: HROW · Real-Time Price · USD
    31.75
    0.75 (2.42%)
    At close: Jun 24, 2025, 3:59 PM
    32.00
    0.79%
    After-hours: Jun 24, 2025, 06:59 PM EDT
    2.42%
    Bid 28.5
    Market Cap 1.17B
    Revenue (ttm) 212.86M
    Net Income (ttm) -21.7M
    EPS (ttm) -0.61
    PE Ratio (ttm) -52.05
    Forward PE 21.16
    Analyst Strong Buy
    Ask 33.5
    Volume 299,659
    Avg. Volume (20D) 489,593
    Open 31.44
    Previous Close 31.00
    Day's Range 30.94 - 31.84
    52-Week Range 20.36 - 59.23
    Beta 0.40

    About HROW

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol HROW
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for HROW stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Harrow Health Inc. is scheduled to release its earnings on Aug 6, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +3.43%
    HROW stock has given up its prior loss. Harrow sha... Unlock content with Pro Subscription
    1 month ago
    +3.43%
    Harrow shares are trading lower after the company reported worse-than-expected Q1 financial results.
    news image

    6 days ago · businesswire.com

    Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

    NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relat...

    news image

    1 week ago · seekingalpha.com

    I Am Swimming In Dividends With +7% Yields

    Winning in gold requires patience and a steady strategy to use the environment to your advantage. The same holds true for investing. Focus on steady dividends over chasing market hype or short-term ga...

    news image

    2 weeks ago · businesswire.com

    Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

    NASHVILLE, Tenn. & TAIPEI, Taiwan--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838....

    news image

    4 weeks ago · seekingalpha.com

    Harrow: Epic Growth & Operating Leverage On Full Display

    Harrow has successfully leveraged its compounding pharmacy roots to drive rapid branded drug growth. Revenue has grown at a steady 40% CAGR for a decade & EBITDA has grown even more sharply. Managemen...

    news image

    1 month ago · businesswire.com

    Harrow to Present at Two Investor Conferences in May

    NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two inves...

    news image

    1 month ago · seekingalpha.com

    Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

    Harrow, Inc. (NASDAQ:HROW ) Q1 2025 Results Conference Call May 9, 2025 8:00 AM ET Company Participants Jamie Webb - Director, Communications & IR Mark Baum - CEO Andrew Boll - CFO Conference Call Par...

    news image

    1 month ago · zacks.com

    Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates

    Harrow (HROW) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.28 per share a year ago.

    news image

    1 month ago · businesswire.com

    Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

    NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first qua...

    news image

    1 month ago · seekingalpha.com

    What Recession? I'm Swimming In Dividends

    What Recession? I'm Swimming In Dividends

    news image

    2 months ago · businesswire.com

    Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

    NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an expansion of its VEVYE® Access for All (“VAFA”) program ...

    Add to Watchlist